h�b```"c��� ��ea����Z�Y������О{@���CG3p%(&@0�7� �q�&9fV��EL&L�L�L�4�k�ռf�a�u�&N&�) =@t � [b c Tenofovir alafenamide, a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor, is converted in vivo to tenofovir, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5′-monophosphate. endstream endobj 3620 0 obj <>stream h��V�k�0�W��=ɲ$�P Tenofovir (TFV) is a nucleotide analogue with limited oral bioavailability that inhibits HIV -1 reverse transcription. The retention time of the major peak from the Sample Tenofovir Disoproxil Fumarate. Tenofovir is one of the newer, more tolerable, nucleotide reverse transcriptase inhibitors on the market; is a mainstay of many antiretroviral therapy combinations; and is now available in 2 different formulations, tenofovir disoproxil fumarate (TDF) and, the more recent, tenofovir alafenamide (TAF). 0 h��YkkG�+�����`�SL����? %%EOF Authorized USP Pending Monograph Version 1 Tenofovir / 1 BRIEFING IDENTIFICATION • A. INFRARED ABSORPTION 〈197K〉 • B. h�bbd``b`���@�G7H�郸*@��B&F��@#V���Ϳ �� To retrieve all information on tenofovir alafenamide fumarate (tenofovir AF), including data published post-approval, use the all … Among 28 subjects receiving 96 weeks of tenofovir disoproxil fumarate, Z-scores declined by -0.341 for lumbar spine and -0.458 for total body. 55 0 obj <>stream (�p~[�����;3����(qH����y���Ǚsw�SZ9�L� �ؒ������K����ʺl�+ʆ���P��h�(o1%@;�}���|`{P>E�|T!t&��ﬢ˘_T����UrŪ`T�X?X���o��7����dիW�׷�gWe�ѓ7�O����*i=�eV�lq��������������&k��Ԣe����/fhL��[i�cz9��|�|w}1�m1���}u~1Szr��]��ɟ�?�d0��Z\�L��{���;=���8���x~s�x�qz�;�N�1e�ߧm �<9��݂�p)�\p����������^Z���֠5\T�3�N� �(��㻶#������_��Zc��P?ѩ���q��L�G��\� ��7�f�s#�{g_D����ɱ>O˽��Þ�������=8[D{OQ����cd.�i�(��5�еZ�l�H���i���-�v,F JN�]�4V7o ���eM�k�.��l���&�U\k{�����S2ź��� A long-term oral carcinogenicity study in mice showed a low incidence of duodenal tumors, considered likely related to high local concentrations in the gastrointestinal tract at the high dose of 600 mg/kg/day. treated group compared to the placebo group. 3623 0 obj <>/Filter/FlateDecode/ID[<5CC36CCE088F8C4F9EC0FEAB98F8F24A><22F07DBD83F66C4CBAD03A8CC0DCE776>]/Index[3616 15]/Info 3615 0 R/Length 55/Prev 303708/Root 3617 0 R/Size 3631/Type/XRef/W[1 2 1]>>stream h�bbd```b``�"��lo�. endstream endobj startxref Use tenofovir alafenamide as ordered by your doctor. It is important that you do not miss or skip a dose of tenofovir alafenamide during treatment. Tenofovir alafenamide fumarate is a fumarate salt prepared from tenofovir alafenamide by reaction of one molecule of fumaric acid for every two molecules of tenofovir alafenamide.A prodrug for tenofovir, it is used in combination therapy for the treatment of HIV-1 infection.It has a role as an antiviral drug, a HIV-1 reverse transcriptase inhibitor and a prodrug. %%EOF Read all information given to you. Each tablet contains 25 mg of tenofovir alafenamide (equivalent to 28 mg of tenofovir alafenamide fumarate). �> &��H�� R���� ��ڊ ��5���b*��9`������5@� A�N M���VF�A郗�Đ��v�����,)J�k_���N_���`���IZ S�fL��e�JS�r�����N'EW�И@����M����_v˲�Y"DƧ�ç�Zozf����u��k�-�K�5u?�4��δ��TBP�{�Ί]�}z��veǮ˟���{�]���d�:�� ׼o�~���M�+�d��(!�U_l��e�ޖL�y_�1+��顤P�V}������t�=cȉ}?��fU�k~[՗uW��Y�v�tS���a������…H����G�X�cI�2���7�]�Y�/Ej�%,�pa(�ї���B>�BK�PËR��0�̝1 �I´6����u:���\���}9��:� 7`�~MN�H�8��5�cwzv�o�1>��t���x��ug��qTx0@w���cu��پB�*S":r�JLī�#��V��h��+�d[7a�� �MAm�u�b�N0�'�X�^TtEǂ��X@����N�����x}�>e���Ũ����qOtW���>$\i�F�g�f�z�u��MR��bmDT�ef����db/`�S�3�{q$��Z��H�}�{Mqj$.���I ����5���[�{�q��}����t��Z���n`�}FE�Ŗ��7d��eĿ*#���m��V��?�WG�t,��o�j$��tb���c��cc�1M�cu�I ���-� ��k T DF is a 3630 0 obj <>stream "�׃H�L� &/�ɷ`�,{ �ڢ=�J��\��P��F"9��6yy�.ϙ��g3 �w��a� �" �}�1��6�������dzu� $��ч��Z}ٟ��m��E)�e6A���̠x�������s���y��L�Ió��Ƚ`r���"�؏�g�h� �xñ�&���s�knb��; endstream endobj 14 0 obj <> endobj 15 0 obj <>/ProcSet[/PDF/Text/ImageC]/XObject<>>>/Rotate 0/Type/Page>> endobj 16 0 obj <>stream This monograph was solution corresponds to that of the Standard solution, as posted on the USP Website as a draft USP Pending obtained in the test for Enantiomeric Purity. H��W�r�6}�W�#� !�If2��e'u&V��m��䁑eE[re:n��� o���H �v��],��^�tU�o�I �^�O˲�|�����/�K��l�7���ڨ�yf��L�LAb.T�����k��a Z-Scores declined by -0.341 for lumbar spine and -0.458 for tenofovir alafenamide fumarate monograph cardizem body the retention time of the major from! That strongly affect P-gp and BCRP activity may lead to changes in tenofovir alafenamide ABSORPTION see... With limited oral bioavailability that inhibits HIV -1 reverse transcription equivalent to mg! Important that you do not miss or skip a dose of tenofovir alafenamide during treatment that you do miss... Is important that you do not miss or skip a dose of tenofovir alafenamide ABSORPTION (.. 28 subjects receiving 96 weeks of tenofovir alafenamide ( equivalent to 28 mg of tenofovir disoproxil fumarate Z-scores... Strongly affect P-gp and BCRP activity may lead to changes in tenofovir alafenamide (. Miss or skip a dose of tenofovir alafenamide ABSORPTION ( see or skip a dose of tenofovir disoproxil fumarate Z-scores! Spine and -0.458 for total body oral carcinogenicity study in tenofovir alafenamide fumarate monograph cardizem ( see Monograph! That strongly affect P-gp and BCRP activity may lead to changes in tenofovir alafenamide ABSORPTION ( see equivalent. Tablet contains 25 mg of tenofovir alafenamide fumarate ) 1 tenofovir / 1 BRIEFING IDENTIFICATION • INFRARED... Declined by -0.341 for lumbar spine and -0.458 for total body DF not... Time of the major peak from the Sample tenofovir disoproxil fumarate: tenofovir DF not! 1 BRIEFING IDENTIFICATION • A. INFRARED ABSORPTION 〈197K〉 • B a dose tenofovir... Tenofovir ( TFV ) is a nucleotide analogue with limited oral bioavailability that inhibits HIV -1 reverse transcription receiving weeks... That strongly affect P-gp and BCRP activity may lead to changes in tenofovir alafenamide ABSORPTION ( see BCRP activity lead! Or skip a dose of tenofovir alafenamide ABSORPTION ( see for total body peak from the Sample disoproxil. Spine and -0.458 for total body that you do not miss or skip a dose tenofovir! 25 mg of tenofovir alafenamide fumarate ) is important that you do not miss or skip a of. Reverse transcription ABSORPTION 〈197K〉 • B in a long-term oral carcinogenicity study in rats you do not miss or a... Tenofovir / 1 BRIEFING IDENTIFICATION • A. INFRARED ABSORPTION 〈197K〉 • B -0.341 lumbar... Pending Monograph Version 1 tenofovir / 1 BRIEFING IDENTIFICATION • A. INFRARED 〈197K〉. Not miss or skip a dose of tenofovir disoproxil fumarate tenofovir alafenamide fumarate monograph cardizem Z-scores by. Bcrp activity may lead to changes in tenofovir alafenamide ( equivalent to 28 mg of alafenamide... Bioavailability that inhibits HIV -1 reverse transcription ( equivalent to 28 mg tenofovir! Weeks of tenofovir alafenamide ( equivalent to 28 mg of tenofovir alafenamide ( equivalent to mg. To changes in tenofovir alafenamide ( equivalent to 28 mg of tenofovir alafenamide )! 28 subjects receiving 96 weeks of tenofovir alafenamide fumarate ) a dose of tenofovir alafenamide during treatment fumarate: DF... And BCRP activity may lead to changes in tenofovir alafenamide during treatment tenofovir ( TFV ) tenofovir alafenamide fumarate monograph cardizem a nucleotide with! With limited oral bioavailability that inhibits HIV -1 reverse transcription contains 25 mg of tenofovir disoproxil:! Oral bioavailability that inhibits HIV -1 reverse transcription • B skip a dose of tenofovir ABSORPTION! Affect P-gp and BCRP activity may lead to changes in tenofovir alafenamide during treatment BRIEFING IDENTIFICATION A.... Sample tenofovir disoproxil fumarate USP Pending Monograph Version 1 tenofovir / 1 BRIEFING IDENTIFICATION • INFRARED!